Results 281 to 290 of about 13,339,631 (403)

Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study. [PDF]

Mol Biomed
Gao Y, Qi F, Zhou W, Jiang P, Hu M, Wang Y, Song C, Han Y, Li D, Qin N, Zhang H, Luo H, Zhang T, Li H.   +13 more
europepmc   +1 more source

Application of a Theory of Enzyme Specificity to Protein Synthesis

, 1958
Daniel E. Koshland
openalex   +1 more source

Abscisic Acid Inhibits Type 2C Protein Phosphatases via the PYR/PYL Family of START Proteins

Science, 2009
Sang-Youl Park, Pauline Fung, N. Nishimura, Davin R. Jensen, Hiroaki Fujii, Yang Zhao, Shelley Lumba, J. Santiago, Américo Rodrigues, T. F. Chow, S. Alfred, D. Bonetta, R. Finkelstein, N. Provart, D. Desveaux, P. L. Rodriguez, P. McCourt, Jian‐Kang Zhu, J. Schroeder, B. Volkman, S. Cutler   +20 more
semanticscholar   +1 more source

RETRACTION: lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway

Molecular Oncology, EarlyView.
RETRACTION: W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, “lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway,” Molecular Oncology 13, no. 10 (2019): 2246–2258, https://doi.org/10.1002/1878-0261.12553.
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Causal Effects of the Plasma Proteome on Vascular Dementia Risk: A Mendelian Randomization Study with Experimental Validation. [PDF]

Cell Mol Neurobiol
Chen Y, Guo C, Liang X, Chi X, Zhang Z, Chang Z, Zhang Y.   +6 more
europepmc   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

SUMOylation: Interplaying with the plant disease triangle. [PDF]

PLoS Pathog
Li C, Yang C, Lai J.
europepmc   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

Exploring the role of inflammation, immunity, and metabolism in colorectal cancer via mendelian randomization approach. [PDF]

Sci Rep
Zhou L, Liao M, Zhang L, Peng T, Han C, Zeng Q, Huan X, Dai A, Gao Z, Li J, Tang J, Chen J, Li Y, Zhang J.   +13 more
europepmc   +1 more source